In particular, immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated significant promise in the treatment of various cancers, including ESCC. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.